NASDAQ:REPL Replimune Group - REPL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $28.45 +0.29 (+1.03%) (As of 02/7/2023 03:25 PM ET) Add Compare Share Share Today's Range$27.92▼$28.8650-Day Range$18.89▼$29.0952-Week Range$13.05▼$29.52Volume97,044 shsAverage Volume390,002 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$51.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Replimune Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside81.7% Upside$51.57 Price TargetShort InterestBearish5.03% of Float Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingSelling Shares$375,450 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.99) to ($3.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector449th out of 1,029 stocksBiological Products, Except Diagnostic Industry70th out of 168 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.57, Replimune Group has a forecasted upside of 81.7% from its current price of $28.38.Amount of Analyst CoverageReplimune Group has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.03% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Replimune Group has recently increased by 2.47%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Replimune Group this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $375,450.00 in company stock.Percentage Held by Insiders23.80% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.83% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to decrease in the coming year, from ($2.99) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -10.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -10.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Replimune Group (NASDAQ:REPL) StockReplimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.Read More Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Stock News HeadlinesFebruary 7, 2023 | finance.yahoo.comReplimune to Present at the Virtual SVB Securities Global Biopharma ConferenceFebruary 3, 2023 | americanbankingnews.comHead-To-Head Analysis: Replimune Group (NASDAQ:REPL) vs. bluebird bio (NASDAQ:BLUE)February 7, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 6, 2023 | finance.yahoo.comRecent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's WhyJanuary 6, 2023 | finance.yahoo.comInstitutional investors may adopt severe steps after Replimune Group, Inc.'s (NASDAQ:REPL) latest 5.3% drop adds to a year lossesJanuary 6, 2023 | finance.yahoo.comWall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a BetJanuary 4, 2023 | it.tmcnet.comReplimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy OfficerJanuary 3, 2023 | finance.yahoo.comReplimune to Present at the 41st Annual J.P. Morgan Healthcare ConferenceFebruary 7, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.December 14, 2022 | finance.yahoo.comReplimune Breaks Out: Could Rise 30% From HereDecember 12, 2022 | finance.yahoo.comAnalyst Beefs Up Replimune Price Target As Recent Data Validates Treatment PlatformDecember 7, 2022 | marketwatch.comReplimune Shares Rally on Pipeline Advances >REPLDecember 7, 2022 | finance.yahoo.comReplimune Shares Surge After Early Data From Pretreated Melanoma PatientsDecember 7, 2022 | marketwatch.comReplimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma >REPLDecember 7, 2022 | seekingalpha.comReplimune in pact with Roche to study cancer drug combosDecember 7, 2022 | finance.yahoo.comReplimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular CarcinomaDecember 7, 2022 | finance.yahoo.comReplimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program UpdateNovember 23, 2022 | finance.yahoo.comReplimune to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 22, 2022 | finance.yahoo.comReplimune to Host Virtual Investor Event on December 7, 2022November 3, 2022 | finanznachrichten.deReplimune Group Inc: Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate UpdateOctober 15, 2022 | finance.yahoo.comReplimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The CatalystsOctober 14, 2022 | markets.businessinsider.comExpert Ratings for Replimune GroupAugust 24, 2022 | finance.yahoo.comBillionaires Are Scooping Up These 3 Beaten-Down Biotech StocksAugust 12, 2022 | seekingalpha.comReplimune: Recent Developments Strengthen Bull ThesisAugust 6, 2022 | finance.yahoo.comIs Replimune Group (NASDAQ:REPL) Using Too Much Debt?July 17, 2022 | uk.finance.yahoo.comReplimune Group, Inc. (REPL)June 3, 2022 | finance.yahoo.comReplimune Announces the Departure of Jason Rhodes from its Board of DirectorsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Company Calendar Last Earnings11/04/2021Today2/07/2023Next Earnings (Estimated)2/09/2023Fiscal Year End3/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Forecast$51.57 High Stock Price Forecast$70.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+81.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.72% Return on Assets-31.86% Debt Debt-to-Equity Ratio0.06 Current Ratio16.12 Quick Ratio16.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.71 per share Price / Book3.27Miscellaneous Outstanding Shares49,740,000Free Float37,901,000Market Cap$1.42 billion OptionableNot Optionable Beta1.65 Key ExecutivesPhilip Astley-SparkeChief Executive Officer & DirectorRobert CoffinPresident & DirectorColin A. LoveChief Operating OfficerJean M. FranchiChief Financial Officer, Secretary & TreasurerPamela EspositoChief Business OfficerKey CompetitorsArcellxNASDAQ:ACLXAdaptive BiotechnologiesNASDAQ:ADPTVericelNASDAQ:VCELIovance BiotherapeuticsNASDAQ:IOVAImmunityBioNASDAQ:IBRXView All CompetitorsInsiders & InstitutionsTD Asset Management IncBought 27,962 shares on 2/7/2023Ownership: 0.267%Emerald Advisers LLCBought 49,455 shares on 2/3/2023Ownership: 2.384%Frazier Life Sciences Management L.P.Bought 125,293 shares on 2/3/2023Ownership: 1.873%Fisher Asset Management LLCBought 14,826 shares on 2/3/2023Ownership: 0.141%SG Americas Securities LLCSold 4,904 shares on 2/2/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions REPL Stock - Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks. What is Replimune Group's stock price forecast for 2023? 7 brokerages have issued twelve-month target prices for Replimune Group's shares. Their REPL share price forecasts range from $34.00 to $70.00. On average, they predict the company's share price to reach $51.57 in the next twelve months. This suggests a possible upside of 81.5% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts. How have REPL shares performed in 2023? Replimune Group's stock was trading at $27.20 at the beginning of the year. Since then, REPL shares have increased by 4.5% and is now trading at $28.42. View the best growth stocks for 2023 here. When is Replimune Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023. View our REPL earnings forecast. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." Who are Replimune Group's major shareholders? Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.38%), Frazier Life Sciences Management L.P. (1.87%), TD Asset Management Inc (0.27%), Moody Aldrich Partners LLC (0.18%), Fisher Asset Management LLC (0.14%) and Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $28.42. How much money does Replimune Group make? Replimune Group (NASDAQ:REPL) has a market capitalization of $1.41 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. How many employees does Replimune Group have? The company employs 152 workers across the globe. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com. This page (NASDAQ:REPL) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.